Accession Number:

ADA524972

Title:

Angiogenesis and Tissue Engineering Research

Descriptive Note:

Final addendum rept. 24 Mar 2009-31 Jul 2010

Corporate Author:

CHILDREN'S HOSPITAL CORP BOSTON MA

Personal Author(s):

• Ingber, Donald
• Puder, Mark
• Bischoff, Joyce

Report Date:

2010-08-01

Pagination or Media Count:

43.0

Abstract:

Centers on the development of new medical therapies and regenerative medicine approaches for the treatment of injured soldiers, and the improvement of the overall health and performance of military personnel. Over the past year we designed to develop aerosol therapies to save lives in patients with pulmonary edema and Acute Respiratory Distress Syndrome ARDS we evaluated the anti-malarial activity of an oral angiogenesis inhibitor developed in past grant funding periods, called Lodamin, that is a methionine aminopeptidases 2 MetAP2inhibitor and, we developed new microsystems technologies to harvest rare circulating stem cells for tissue engineering applications, such as blood vessel precursor cells for tissue revascularization.

Descriptors:

• *MEDICAL RESEARCH
• ARMY PERSONNEL
• SIGNS AND SYMPTOMS
• ANGIOGENESIS
• WOUNDS AND INJURIES
• GENETIC ENGINEERING
• TISSUES(BIOLOGY)
• THERAPY

Subject Categories:

• Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE